Among people with immune-related diseases like MS, being female alone did not raise the chance of having high depressive symptoms; smoking and anxiety were stronger links to depression.
Researchers looked at 652 people with immune-related diseases, including conditions like multiple sclerosis (MS), and found 36% had elevated depressive symptoms — about 1 in 3 people.Women did not have higher odds of elevated depressive symptoms than men once other factors were considered, meaning sex by itself wasn't the main driver.Men were more likely than women to report feeling cheerful on one of the depression questions, showing that individual mood questions can differ by sex.Smoking and higher anxiety symptoms were linked to a greater chance of having elevated depressive symptoms, suggesting these are important risk factors to watch.The study used brief depression questionnaires and disease-specific cutoffs to find people at higher risk, which can help identify those who may benefit from extra support or treatment.
People with MS and their caregivers should care because the study highlights that depression is common (about 1 in 3) and not just tied to being female — so anyone with MS could be at risk.If you or someone you care for smokes or has signs of anxiety (worry, restlessness, trouble sleeping), this study suggests those issues raise the chance of having more depressive symptoms.Healthcare providers and MS care teams can use this information to screen for depression more broadly, not just based on a person’s sex, and pay special attention to smoking and anxiety.For everyday life, this means checking mood regularly (like asking simple questions during visits) and addressing smoking or anxiety early — similar to fixing a leaky roof before water damage spreads.Caregivers can use this as a reminder to watch for changes in mood, sleep, or worry in the person they help, and encourage talking to a clinician when needed.
This study used questionnaires, not full psychiatric interviews, so it identifies elevated depressive symptoms rather than a formal diagnosis of depression.The results come from people in one region (Manitoba, Canada) and from several immune diseases grouped together, so findings might differ in other places or in just MS alone.Because the study is observational, it shows links (for example, between smoking and more depressive symptoms) but cannot prove that one thing causes the other.
12/31/2026
Learn how certain gut bacteria can worsen MS symptoms and what this means for treatment and daily li
Read More12/1/2026
Discover how the CEAM tool aids in understanding DNA changes in brain cells, offering hope for bette
Read More3/1/2026
Early OCT eye scans can often distinguish MOGAD from NMOSD optic neuritis, helping guide faster trea
Read More3/1/2026
Learn about the risks of enterovirus encephalitis for MS patients on ocrelizumab and how early recog
Read More3/1/2026
Learn how TREM2 helps brain immune cells switch to a repair mode, reduce inflammation, and may suppo
Read More3/1/2026
Discover how new research could help women with MS produce more IL-10, an important substance for co
Read MoreWhether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of health psychology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.